Immunome Stock Analysis

IMNM Stock  USD 10.40  0.03  0.29%   
Immunome is undervalued with Real Value of 15.04 and Target Price of 30.0. The main objective of Immunome stock analysis is to determine its intrinsic value, which is an estimate of what Immunome is worth, separate from its market price. There are two main types of Immunome's stock analysis: fundamental analysis and technical analysis.
Long Term DebtCash325.0K113.0K134.0K120.6K152.5K1.6M2.5M39.8M113.5M119.2M100%
The Immunome stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immunome is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Immunome Stock trading window is adjusted to America/New York timezone.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

Immunome Stock Analysis Notes

About 19.0% of the company shares are held by company insiders. The book value of Immunome was currently reported as 3.56. The company recorded a loss per share of 7.94. Immunome had not issued any dividends in recent years. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. To learn more about Immunome call Purnanand Sarma at 610 321 3700 or check out https://immunome.com.

Immunome Investment Alerts

Immunome had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with loss before overhead, payroll, taxes, and interest of (81 M).
Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86.
Immunome has a frail financial position based on the latest SEC disclosures
Roughly 63.0% of the company shares are owned by institutional investors
Latest headline from bizjournals.com: Philadelphia biotech firm backed by more than 130M names new CEO

Immunome Upcoming and Recent Events

21st of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Immunome Largest EPS Surprises

Earnings surprises can significantly impact Immunome's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-16
2021-06-30-0.39-0.46-0.0717 
2024-08-09
2024-06-30-0.39-0.49-0.125 
2021-03-25
2020-12-31-0.29-0.4-0.1137 
View All Earnings Estimates

Immunome Environmental, Social, and Governance (ESG) Scores

Immunome's ESG score is a quantitative measure that evaluates Immunome's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Immunome's operations that may have significant financial implications and affect Immunome's stock price as well as guide investors towards more socially responsible investments.

Immunome Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Opaleye Management Inc2024-09-30
1.2 M
Geode Capital Management, Llc2024-09-30
1.2 M
Woodline Partners Lp2024-09-30
924.4 K
Avidity Partners Management Lp2024-09-30
873.9 K
Brown Advisory Holdings Inc2024-09-30
860.8 K
Tang Capital Management Llc2024-09-30
720 K
Sofinnova Ventures2024-09-30
676.8 K
Goldman Sachs Group Inc2024-09-30
568.5 K
Northern Trust Corp2024-09-30
473.3 K
T. Rowe Price Investment Management,inc.2024-09-30
5.8 M
Redmile Group, Llc2024-09-30
4.9 M
Note, although Immunome's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunome Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 880.62 M.

Immunome Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.65)(0.68)
Return On Capital Employed(0.78)(0.82)
Return On Assets(0.65)(0.68)
Return On Equity(1.02)(1.08)

Management Efficiency

Immunome has return on total asset (ROA) of (0.3989) % which means that it has lost $0.3989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7636) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of February 2025, Return On Tangible Assets is likely to drop to -0.68. In addition to that, Return On Capital Employed is likely to drop to -0.82. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 18th of February 2025, Other Current Assets is likely to grow to about 7.6 M, while Non Current Assets Total are likely to drop about 2.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 5.44  5.71 
Tangible Book Value Per Share 5.44  5.71 
Enterprise Value Over EBITDA(3.67)(3.85)
Price Book Value Ratio 1.59  0.82 
Enterprise Value Multiple(3.67)(3.85)
Price Fair Value 1.59  0.82 
Enterprise Value103.8 M109 M
Leadership effectiveness at Immunome is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin
(15.06)
Beta
1.904
Return On Assets
(0.40)
Return On Equity
(2.76)

Technical Drivers

As of the 18th of February 2025, Immunome retains the Market Risk Adjusted Performance of (0.11), risk adjusted performance of (0.02), and Standard Deviation of 5.26. Immunome technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Immunome variance and potential upside to decide if Immunome is priced fairly, providing market reflects its last-minute price of 10.4 per share. Given that Immunome has information ratio of (0.04), we strongly advise you to confirm Immunome's regular market performance to make sure the company can sustain itself at a future point.

Immunome Price Movement Analysis

Execute Study
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunome middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunome. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
JavaScript chart by amCharts 3.21.15Dec2025FebJanJan 13Jan 20Jan 27FebFeb 10Feb 1791011121314 1M2M3M4M 42K42.5K43K43.5K44K44.5K Show all
JavaScript chart by amCharts 3.21.15Immunome Volume Immunome Closing Prices Dow Jones Industrial Closing Prices - Benchmark Immunome Bollinger Bands - RealUpperBand Immunome Bollinger Bands - RealMiddleBand Immunome Bollinger Bands - RealLowerBand

Immunome Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunome insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunome Outstanding Bonds

Immunome issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunome uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunome bonds can be classified according to their maturity, which is the date when Immunome has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Immunome Predictive Daily Indicators

Immunome intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunome stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunome Corporate Filings

14th of February 2025
Other Reports
ViewVerify
4th of February 2025
Other Reports
ViewVerify
3rd of February 2025
Other Reports
ViewVerify
30th of January 2025
Other Reports
ViewVerify
8K
29th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
23rd of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
25th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
ASR
22nd of November 2024
Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC)
ViewVerify

Immunome Forecast Models

Immunome's time-series forecasting models are one of many Immunome's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunome's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Immunome Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunome prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immunome. By using and applying Immunome Stock analysis, traders can create a robust methodology for identifying Immunome entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(6.86)(7.20)
Operating Profit Margin(7.03)(7.38)
Net Loss(6.86)(7.20)
Gross Profit Margin(0.57)(0.60)

Current Immunome Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
30.0Strong Buy7Odds
Immunome current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunome, talking to its executives and customers, or listening to Immunome conference calls.
JavaScript chart by amCharts 3.21.1552Strong BuyBuy1.52.02.53.03.54.04.55.0
Immunome Analyst Advice Details

Immunome Stock Analysis Indicators

Immunome stock analysis indicators help investors evaluate how Immunome stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunome shares will generate the highest return on investment. By understating and applying Immunome stock analysis, traders can identify Immunome position entry and exit signals to maximize returns.
Begin Period Cash Flow20.4 M
Common Stock Shares Outstanding19.8 M
Total Stockholder Equity119.9 M
Property Plant And Equipment Net3.6 M
Cash And Short Term Investments138.1 M
Cash98.7 M
Accounts Payable3.3 M
Net Debt-97 M
50 Day M A11.136
Total Current Liabilities21.8 M
Other Operating Expenses123.5 M
Non Current Assets Total3.8 M
Non Currrent Assets Other100 K
Stock Based Compensation6.2 M
When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.94)
Revenue Per Share
0.189
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.40)
Return On Equity
(2.76)
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Discover investing ideas

Utilize additional investing modules